Prof. Dr. Werner Albrich
Leitende(r) Arzt/Ärztin
Infektiologie | Infektionsprävention | Reisemedizin · Dept. I
How representative is a point-of-care randomized trial? Clinical outcomes of patients excluded from a point-of-care randomized controlled trial evaluating antibiotic duration for Gram-negative bacteraemia: a multicentre prospective observational cohort study
Rossel A, Zandberg K, Albrich W, Huttner A. How representative is a point-of-care randomized trial? Clinical outcomes of patients excluded from a point-of-care randomized controlled trial evaluating antibiotic duration for Gram-negative bacteraemia: a multicentre prospective observational cohort study. Clin Microbiol Infect 2021; 28:297.e1-297.e6.
08.06.2021How representative is a point-of-care randomized trial? Clinical outcomes of patients excluded from a point-of-care randomized controlled trial evaluating antibiotic duration for Gram-negative bacteraemia: a multicentre prospective observational cohort study
08.06.2021Clin Microbiol Infect 2021; 28:297.e1-297.e6
Rossel Anne, Zandberg Kimberly P M, Albrich Werner, Huttner Angela
Non-occupational and occupational factors associated with specific SARS-CoV-2 antibodies among hospital workers - A multicentre cross-sectional study
Kahlert C, Albrich W, Babouee Flury B, Besold U, Fehr J, Kuster S, McGeer A, Risch L, Schlegel M, Friedl A, Vernazza P, Wiggli B, Vuichard-Gysin D, Stocker R, Persi R, Güsewell S, Egger T, Leal-Neto O, Sumer J, Flury D, Brucher A, Lemmenmeier E, Möller J, Rieder P, Kohler P. Non-occupational and occupational factors associated with specific SARS-CoV-2 antibodies among hospital workers - A multicentre cross-sectional study. Clin Microbiol Infect 2021; 27:1336-1344.
19.05.2021Non-occupational and occupational factors associated with specific SARS-CoV-2 antibodies among hospital workers - A multicentre cross-sectional study
19.05.2021Clin Microbiol Infect 2021; 27:1336-1344
Kahlert Christian, Albrich Werner, Babouee Flury Baharak, Besold Ulrike, Fehr Jan, Kuster Stefan, McGeer Allison, Risch Lorenz, Schlegel Matthias, Friedl Andree, Vernazza Pietro, Wiggli Benedikt, Vuichard-Gysin Danielle, Stocker Reto, Persi Raphael, Güsewell Sabine, Egger Thomas, Leal-Neto Onicio B, Sumer Johannes, Flury Domenica, Brucher Angela, Lemmenmeier Eva, Möller J Carsten, Rieder Philip, Kohler Philipp
The Impact of Pneumococcal Conjugate Vaccine (PCV) Coverage Heterogeneities on the Changing Epidemiology of Invasive Pneumococcal Disease in Switzerland, 2005-2019
Oyewole O, Lang P, Albrich W, Wissel K, Leib S, Casanova C, Hilty M. The Impact of Pneumococcal Conjugate Vaccine (PCV) Coverage Heterogeneities on the Changing Epidemiology of Invasive Pneumococcal Disease in Switzerland, 2005-2019. Microorganisms 2021; 9
18.05.2021The Impact of Pneumococcal Conjugate Vaccine (PCV) Coverage Heterogeneities on the Changing Epidemiology of Invasive Pneumococcal Disease in Switzerland, 2005-2019
18.05.2021Microorganisms 2021; 9
Oyewole Oluwaseun Rume-Abiola, Lang Phung, Albrich Werner, Wissel Kerstin, Leib Stephen L, Casanova Carlo, Hilty Markus
Characteristics of patients with Coronavirus Disease 2019 (COVID-19) and seasonal influenza at time of hospital admission: a single center comparative study
Sieber P, Vernazza P, Sieber R, Schlegel M, Gardiol C, Boggian K, Albrich W, Güsewell S, Flury D, Kohler P. Characteristics of patients with Coronavirus Disease 2019 (COVID-19) and seasonal influenza at time of hospital admission: a single center comparative study. BMC Infect Dis 2021; 21:271.
17.03.2021Characteristics of patients with Coronavirus Disease 2019 (COVID-19) and seasonal influenza at time of hospital admission: a single center comparative study
17.03.2021BMC Infect Dis 2021; 21:271
Sieber Pablo, Vernazza Pietro, Sieber Robert, Schlegel Matthias, Gardiol Céline, Boggian Katia, Albrich Werner, Güsewell Sabine, Flury Domenica, Kohler Philipp
The Effects of Corticosteroids on the Respiratory Microbiome: A Systematic Review
Hartmann J, Albrich W, Dmitrijeva M, Kahlert C. The Effects of Corticosteroids on the Respiratory Microbiome: A Systematic Review. Front Med (Lausanne) 2021; 8:588584.
10.03.2021The Effects of Corticosteroids on the Respiratory Microbiome: A Systematic Review
10.03.2021Front Med (Lausanne) 2021; 8:588584
Hartmann Julia E, Albrich Werner, Dmitrijeva Marija, Kahlert Christian
Strain-Resolved Dynamics of the Lung Microbiome in Patients with Cystic Fibrosis
Dmitrijeva M, Kahlert C, Feigelman R, Kleiner R, Nolte O, Albrich W, Baty F, Von Mering C. Strain-Resolved Dynamics of the Lung Microbiome in Patients with Cystic Fibrosis. MBio 2021; 12
09.03.2021Strain-Resolved Dynamics of the Lung Microbiome in Patients with Cystic Fibrosis
09.03.2021MBio 2021; 12
Dmitrijeva Marija, Kahlert Christian, Feigelman Rounak, Kleiner Rebekka L, Nolte Oliver, Albrich Werner, Baty Florent, Von Mering Christian
HSV-pneumonitis in a patient with lung cancer receiving check point inhibitors - a case report
Sumer J, Waldeck F, Fischer N, Appenzeller C, Koster M, Früh M, Albrich W. HSV-pneumonitis in a patient with lung cancer receiving check point inhibitors - a case report. Pneumonia (Nathan) 2021; 13:1.
25.01.2021HSV-pneumonitis in a patient with lung cancer receiving check point inhibitors - a case report
25.01.2021Pneumonia (Nathan) 2021; 13:1
Sumer Johannes, Waldeck Frederike, Fischer Nadja, Appenzeller Christina, Koster Markus, Früh Martin, Albrich Werner
Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19)
Urwyler P, Sendi P, Albrich W, Stüssi-Helbling M, Huber L, Bacci M, Camacho-Ortiz A, Sumer J, Thoma R, Trendelenburg M, Heijnen I, Moser S, Charitos P, Osthoff M. Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19). Trials 2021; 22:1.
04.01.2021Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19)
04.01.2021Trials 2021; 22:1
Urwyler Pascal, Sendi Parham, Albrich Werner, Stüssi-Helbling Melina, Huber Lars C, Bacci Marcelo R, Camacho-Ortiz Adrián, Sumer Johannes, Thoma Reto, Trendelenburg Marten, Heijnen Ingmar A F M, Moser Stephan, Charitos Panteleimon, Osthoff Michael
Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies
Hasan Ali O, Penninger J, Bergthaler A, Popa A, Gómez-Mejia A, Schüpbach R, Bühler P, Vernazza P, Kahlert C, Kohler P, Albrich W, Kern L, Thiel S, Weber M, Paprotny M, Brugger S, Risch L, Bomze D, Flatz L. Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies. Clin Infect Dis 2021; 73:e2869-e2874.
02.01.2021Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies
02.01.2021Clin Infect Dis 2021; 73:e2869-e2874
Hasan Ali Omar, Penninger Josef M, Bergthaler Andreas, Popa Alexandra M, Gómez-Mejia Alejandro, Schüpbach Reto A, Bühler Philipp K, Vernazza Pietro, Kahlert Christian, Kohler Philipp, Albrich Werner, Kern Lukas, Thiel Sarah, Weber Myriam, Paprotny Matthias, Brugger Silvio D, Risch Lorenz, Bomze David, Flatz Lukas
Acute respiratory distress syndrome during the COVID-19 pandemic: not only SARS-CoV-2
Meyer Sauteur P, Kleger G, Albrich W. Acute respiratory distress syndrome during the COVID-19 pandemic: not only SARS-CoV-2. New Microbes New Infect 2021; 40:100836.
01.01.2021Acute respiratory distress syndrome during the COVID-19 pandemic: not only SARS-CoV-2
01.01.2021New Microbes New Infect 2021; 40:100836
Meyer Sauteur P M, Kleger Gian-Reto, Albrich Werner
Author Correction: In vitro virucidal activity of Echinaforce, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2
Signer J, Schoop R, Suter A, Siegrist D, Lenz N, Ackermann-Gäumann R, Ryter S, Züst R, Strasser M, Albrich W, Jonsdottir H, Engler O. Author Correction: In vitro virucidal activity of Echinaforce, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2. Virol J 2020; 17:172.
09.11.2020Author Correction: In vitro virucidal activity of Echinaforce, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2
09.11.2020Virol J 2020; 17:172
Signer Johanna, Schoop Roland, Suter Andreas, Siegrist Denise, Lenz Nicole, Ackermann-Gäumann Rahel, Ryter Sarah, Züst Roland, Strasser Marc, Albrich Werner, Jonsdottir Hulda R, Engler Olivier B
Prevalence of SARS-CoV-2 antibodies among Swiss hospital workers: Results of a prospective cohort study
Kohler P, Schlegel M, Risch L, Kuster S, McGeer A, Babouee Flury B, Albrich W, Notter J, Leal-Neto O, Güsewell S, Flury D, Sumer J, Kahlert C, Vernazza P. Prevalence of SARS-CoV-2 antibodies among Swiss hospital workers: Results of a prospective cohort study. Infect Control Hosp Epidemiol 2020; 42:604-608.
08.10.2020Prevalence of SARS-CoV-2 antibodies among Swiss hospital workers: Results of a prospective cohort study
08.10.2020Infect Control Hosp Epidemiol 2020; 42:604-608
Kohler Philipp, Schlegel Matthias, Risch Lorenz, Kuster Stefan, McGeer Allison, Babouee Flury Baharak, Albrich Werner, Notter Julia, Leal-Neto Onicio B, Güsewell Sabine, Flury Domenica, Sumer Johannes, Kahlert Christian, Vernazza Pietro
In vitro virucidal activity of Echinaforce®, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2
Signer J, Schoop R, Suter A, Siegrist D, Lenz N, Ackermann-Gäumann R, Ryter S, Züst R, Strasser M, Albrich W, Jonsdottir H, Engler O. In vitro virucidal activity of Echinaforce®, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2. Virol J 2020; 17:136.
09.09.2020In vitro virucidal activity of Echinaforce®, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2
09.09.2020Virol J 2020; 17:136
Signer Johanna, Schoop Roland, Suter Andreas, Siegrist Denise, Lenz Nicole, Ackermann-Gäumann Rahel, Ryter Sarah, Züst Roland, Strasser Marc, Albrich Werner, Jonsdottir Hulda R, Engler Olivier B
Influenza-associated aspergillosis in critically-ill patients-a retrospective bicentric cohort study
Waldeck F, Kleger G, Pugin J, Maggiorini M, Boggian K, Schrenzel J, Kaiser L, Iten A, Notter J, Flury D, Wendel Garcia P, Suh N, Boroli F, Albrich W. Influenza-associated aspergillosis in critically-ill patients-a retrospective bicentric cohort study. Eur J Clin Microbiol Infect Dis 2020; 39:1915-1923.
03.06.2020Influenza-associated aspergillosis in critically-ill patients-a retrospective bicentric cohort study
03.06.2020Eur J Clin Microbiol Infect Dis 2020; 39:1915-1923
Waldeck Frederike, Kleger Gian-Reto, Pugin Jérôme, Maggiorini Marco, Boggian Katia, Schrenzel Jacques, Kaiser Laurent, Iten Anne, Notter Julia, Flury Domenica, Wendel Garcia Pedro David, Suh Noémie, Boroli Filippo, Albrich Werner
Effect of C-Reactive Protein-Guided Antibiotic Treatment Duration, 7-Day Treatment, or 14-Day Treatment on 30-Day Clinical Failure Rate in Patients With Uncomplicated Gram-Negative Bacteremia: A Randomized Clinical Trial
von Dach E, Bochud P, Kaiser L, Harbarth S, Rossel A, McCallin S, Lemmenmeier E, Kohler P, Huttner B, Gayet-Ageron A, Flury D, Cuvelier C, Prendki V, Brunel A, Albrich W, Huttner A. Effect of C-Reactive Protein-Guided Antibiotic Treatment Duration, 7-Day Treatment, or 14-Day Treatment on 30-Day Clinical Failure Rate in Patients With Uncomplicated Gram-Negative Bacteremia: A Randomized Clinical Trial. JAMA 2020; 323:2160-2169.
02.06.2020Effect of C-Reactive Protein-Guided Antibiotic Treatment Duration, 7-Day Treatment, or 14-Day Treatment on 30-Day Clinical Failure Rate in Patients With Uncomplicated Gram-Negative Bacteremia: A Randomized Clinical Trial
02.06.2020JAMA 2020; 323:2160-2169
von Dach Elodie, Bochud Pierre-Yves, Kaiser Laurent, Harbarth Stephan, Rossel Anne, McCallin Shawna, Lemmenmeier Eva, Kohler Philipp, Huttner Benedikt, Gayet-Ageron Angèle, Flury Domenica, Cuvelier Clémence, Prendki Virginie, Brunel Anne-Sophie, Albrich Werner, Huttner Angela
Levofloxacin prophylaxis in patients with myeloma
Albrich W, Boggian K. Levofloxacin prophylaxis in patients with myeloma. Lancet Oncol 2020; 21:e68.
01.02.2020Levofloxacin prophylaxis in patients with myeloma
01.02.2020Lancet Oncol 2020; 21:e68
Albrich Werner, Boggian Katia
Die präoperative Urinkultur variiert von der Stentkultur bei Patienten mit permanenter DJ-Katheter-Versorgung
Zumstein V, Ren Q, Schmid H, Engeler D, Güsewell S, Nolte O, Albrich W, Buhmann M, Betschart P, Abt D. Die präoperative Urinkultur variiert von der Stentkultur bei Patienten mit permanenter DJ-Katheter-Versorgung. Swiss Urol 2020:29.
01.01.2020Die präoperative Urinkultur variiert von der Stentkultur bei Patienten mit permanenter DJ-Katheter-Versorgung
01.01.2020Swiss Urol 2020:29
Zumstein Valentin, Ren Q, Schmid Hans-Peter, Engeler Daniel, Güsewell Sabine, Nolte O, Albrich Werner, Buhmann MT, Betschart Patrick, Abt Dominik
Species-specificity preliminary evaluation of an IL-4 based test for the differential diagnosis of human echinococcosis
Petrone L, Albrich W, Tamarozzi F, Frischknecht M, Gomez-Morales M, Teggi A, Hoffmann M, Goletti D. Species-specificity preliminary evaluation of an IL-4 based test for the differential diagnosis of human echinococcosis. Parasite Immunol 2019:e12695.
29.12.2019Species-specificity preliminary evaluation of an IL-4 based test for the differential diagnosis of human echinococcosis
29.12.2019Parasite Immunol 2019:e12695
Petrone Linda, Albrich Werner, Tamarozzi Francesca, Frischknecht Manuel, Gomez-Morales Maria Angeles, Teggi Antonella, Hoffmann Matthias, Goletti Delia
Influence of Older Age and Other Risk Factors on Pneumonia Hospitalization in Switzerland in the Pneumococcal Vaccine Era
Albrich W, Rassouli F, Waldeck F, Christoph B, Baty F. Influence of Older Age and Other Risk Factors on Pneumonia Hospitalization in Switzerland in the Pneumococcal Vaccine Era. Front Med (Lausanne) 2019; 6:286.
05.12.2019Influence of Older Age and Other Risk Factors on Pneumonia Hospitalization in Switzerland in the Pneumococcal Vaccine Era
05.12.2019Front Med (Lausanne) 2019; 6:286
Albrich Werner, Rassouli Frank, Waldeck Frederike, Christoph Berger, Baty Florent
Detection of microbial colonization of the urinary tract of patients prior to secondary ureterorenoscopy is highly variable between different types of assessment: results of a prospective observational study
Zumstein V, Qun R, Schmid H, Engeler D, Güsewell S, Nolte O, Albrich W, Buhmann M, Betschart P, Abt D. Detection of microbial colonization of the urinary tract of patients prior to secondary ureterorenoscopy is highly variable between different types of assessment: results of a prospective observational study. Biofouling 2019:1-10.
27.11.2019Detection of microbial colonization of the urinary tract of patients prior to secondary ureterorenoscopy is highly variable between different types of assessment: results of a prospective observational study
27.11.2019Biofouling 2019:1-10
Zumstein Valentin, Qun Ren, Schmid Hans-Peter, Engeler Daniel, Güsewell Sabine, Nolte Oliver, Albrich Werner, Buhmann Matthias T, Betschart Patrick, Abt Dominik